A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Active, not recruiting · NCT04691154 · Registry updated 2026-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Aspiration, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-04-01 | NCT04691154 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Liquidia Technologies, Inc. | 7 |
| PPD Development, LP | 27 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Arizona Pulmonary Specialists | Scottsdale | United States | 1 |
| Baylor Scott and White Research Institute | Temple | United States | 4 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 5 |
| Mayo Clinic Jacksonville | Jacksonville | United States | 67 |
| Summit Health Eastside Clinic | Bend | United States | 2 |
| University of Cincinnati Medical Center | Cincinnati | United States | 27 |
| University of South Florida | Tampa | United States | 65 |
| VA Greater Los Angeles Healthcare | Los Angeles | United States | 1 |